OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE

被引：0
|
作者：
Heron, Louise [1 ]
Chouaid, Christos [2 ]
Vergnenegre, Alain
Bischoff, Helge [3 ]
Walzer, Stefan [4 ]
机构：
[1] Mapi Values, Value Sight & Commun, Boston, MA USA
[2] Hop St Antoine, Lille, France
[3] Univ Heidelberg, Thoraxklin, D-6900 Heidelberg, Germany
[4] F Hoffmann La Roche Pharmaceut AG, Basel, Switzerland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Progression; survival; endpoints;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1447 / S1448
页数：2
相关论文
共 50 条
  • [41] Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.
    Foster, N. R.
    Qi, Y.
    Shi, Q.
    Krook, J. E.
    Kugler, J. W.
    Jett, J. R.
    Molina, J. R.
    Schild, S. E.
    Adjei, A. A.
    Mandrekar, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials
    Foster, N. R.
    Qi, Y.
    Krook, J. E.
    Kugler, J. W.
    Kuross, S. A.
    Jett, J. R.
    Molina, J. R.
    Schild, S. E.
    Adjei, A. A.
    Mandrekar, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Relationship between age treatment and overall survival in patients with non-small cell lung cancer (NSCLC)
    Heras, P.
    Hatzopoulos, A.
    Kritikos, K.
    Georgopoulou, A.
    LUNG CANCER, 2007, 55 : S10 - S10
  • [44] Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC).
    Suk, R
    Park, S
    Liu, G
    Cogan-Drew, T
    Zhou, W
    Su, L
    Lynch, T
    Wain, J
    Christiani, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 842S - 842S
  • [45] Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice
    Martin Faehling
    Birgit Schwenk
    Sebastian Kramberg
    Sabine Fallscheer
    Matthias Leschke
    Jörn Sträter
    Robert Eckert
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 2059 - 2066
  • [46] Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice
    Faehling, Martin
    Schwenk, Birgit
    Kramberg, Sebastian
    Fallscheer, Sabine
    Leschke, Matthias
    Straeter, Joern
    Eckert, Robert
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (10) : 2059 - 2066
  • [47] A PREDICTIVE PATIENT-LEVEL SURROGACY MODEL BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH PRE-TREATED ADVANCED OR METASTATIC (A/M) NON-SMALL-CELL LUNG CANCER (NSCLC) WITH A KRASG12C MUTATION
    Berardi, A.
    Maciel, D.
    Cope, S.
    Mastikhina, L.
    Lee, A.
    VALUE IN HEALTH, 2024, 27 (12)
  • [48] Final Progression-Free Survival (PFS), Updated Overall Survival (OS), And Safety Data from the Global, Randomized, Phase 3 Alex Study of Alectinib (ALC) Versus Crizotinib (CRZ) in Untreated Advanced ALK plus Non-Small Cell Lung Cancer (NSCLC)
    Hoffknecht, Petra
    Mok, Tony
    Shaw, Alice I.
    Camidge, D. Ross
    Gadgeel, Shirish
    Rosell, Rafael
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Perol, Maurice
    Ou, Sai-Hong
    Bordogna, Walter
    Smoljanovic, Vlatka
    Hilton, Magalie
    Peters, Solange
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
  • [49] Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
    Takaya Yamamoto
    Yoko Tsukita
    Yu Katagiri
    Haruo Matsushita
    Rei Umezawa
    Yojiro Ishikawa
    Noriyoshi Takahashi
    Yu Suzuki
    Kazuya Takeda
    Eisaku Miyauchi
    Ryota Saito
    Yoshiyuki Katsuta
    Noriyuki Kadoya
    Keiichi Jingu
    BMC Cancer, 22
  • [50] Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
    Yamamoto, Takaya
    Tsukita, Yoko
    Katagiri, Yu
    Matsushita, Haruo
    Umezawa, Rei
    Ishikawa, Yojiro
    Takahashi, Noriyoshi
    Suzuki, Yu
    Takeda, Kazuya
    Miyauchi, Eisaku
    Saito, Ryota
    Katsuta, Yoshiyuki
    Kadoya, Noriyuki
    Jingu, Keiichi
    BMC CANCER, 2022, 22 (01)
12345